About KEYTRUDA in triple-negative breast cancer (TNBC)
Neoadjuvant KEYTRUDA® (pembrolizumab) + chemotherapy followed by adjuvant KEYTRUDA monotherapy in patients with triple-negative breast cancer (TNBC)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
|Locally advanced or early-stage triple-negative breast cancer, at high risk of recurrence.1|
|For use in ||KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced or early-stage triple-negative breast cancer, at high risk of recurrence.1|
|Dosing schedule ||The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.1|
|Duration of treatment ||Patients should be treated with KEYTRUDA until disease progression or unacceptable toxicity.1|
|Clinical trial||KEYNOTE-522 was a Phase 3 randomised (2:1), double-blind, multicentre, placebo-controlled study, evaluating the efficacy and safety of KEYTRUDA in combination with chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide), given as a neoadjuvant treatment and continued as monotherapy as adjuvant treatment after surgery, in newly diagnosed, previously untreated, high-risk early-stage TNBC patients (N=1,174).1|
Access the KEYNOTE-522 clinical data presentation above.
Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.
- KEYTRUDA Summary of Product Characteristics.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website